EnVivo drug test reveals Alzheimer’s reversal

By Mass High Tech staff

Video Gallery

MHT's Marc Songini: Technology to keep seniors healthy

MHT's Marc Songini: Researchers focus on macular degeneration

Gen9 receives $395K in debt financing [May 22, 2012]

Report: Foreign countries want to lure US biotechs [May 21, 2012]

Former Secretaries Rubin, Paulson to speak at BIO [May 21, 2012]

XenneX completes merger with LifeMap Sciences [May 21, 2012]

Watertown drug developer EnVivo Pharmaceuticals Inc. has announced positive results, including a reversal of behavior characteristic of Alzheimer’s disease in animal testing, for its drug candidate EVP-0962.

The drug, a gamma-secretase modulator, is designed to block production of the peptide AB42, which is associated with Alzheimer’s. According to EnVivo officials, EVP-0962 works with one dose and does so without inhibiting other normal functions.

The results have prompted EnVivo to go into preclinical development in anticipation of clinical trials in 2010.

Privately held EnVivo focuses on drug development related to central nervous system disorders, including Huntington’s disease, in addition to schizophrenia and Alzheimer’s disease. The company last received funding in the amount of $65 million from a fourth-round venture capital financing, led by Fidelity Biosciences. In April, the company announced that it had signed a licensing agreement for its schizophrenia and Alzheimer’s disease treatment, EVP-6124, with Mitsubishi Tanabe Pharma Corp. (MTPC).

Comments

If you are commenting using a Facebook account, your profile information may be displayed with your comment depending on your privacy settings. By leaving the 'Post to Facebook' box selected, your comment will be published to your Facebook profile in addition to the space below.